<DOC>
	<DOCNO>NCT02622555</DOCNO>
	<brief_summary>Overactive bladder syndrome complicate life many woman . 60-70 % woman report improvement treatment antikolinergic treatment often limited adverse event , example dry mouth , obstipation urinary retention . Mirabegron b3-adrenoreceptor agonist induces detrusor relaxation . Earlier study demonstrate similar efficacy compare Mirabegron antimuscarinics significant reduction adverse event . The aim present study survey cardiovascular adverse event Mirabegron treatment general population suffer overactive bladder syndrome .</brief_summary>
	<brief_title>Cardiovascular Morbidity During Treatment Overactive Bladder With B3 Agonists</brief_title>
	<detailed_description>Overactive bladder syndrome complicate life many woman . For 30 year dominant treatment overactive bladder syndrome antimuscarinics first-line pharmacotherapy . 60-70 % woman report improvement treatment therapy limited adverse event , example dry mouth , obstipation urin retention . In Sweden , prescription antimuscarinics increase 69 % period 2000-2007 implies increase desire seek treatment . Mirabegron b3-adrenoreceptor agonist induces detrusor relaxation . Earlier study demonstrate similar efficacy compare Mirabegron antimuscarinics significant reduction adverse event . Clinical phase I-III trial register increased pulse rate effect blood pressure patient . The aim present study survey cardiovascular adverse event treatment Mirabegron general population suffer overactive bladder syndrome .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Inclusion Criteria Overactive bladder syndrome , eligible Mirabegron treatment As specified regulatory authority drug prescription</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>